On April 16, 2015, Mallinckrodt Pharmaceuticals acquired Ikaria, Inc., extending Mallinckrodt’s footprint in the hospital market and expanding its reach into neonatal critical care with INOMAX® (nitric oxide for inhalation), a vital treatment option for a highly vulnerable patient population. It also accelerates Mallinckrodt’s rapid growth in specialty brands - adding significant portfolio diversity with a high-value integrated “drug-device-service” product offering.
Individually approved and marketed together as a drug-device combination, INOMAX and proprietary INOMAX delivery systems will benefit from Mallinckrodt’s larger hospital presence, regulatory expertise, long experience in complex drug and device manufacturing, and support of similar medication-technology pairings.
For information on INOMAX and its delivery systems, please visit www.INOMAX.com.
For customer support and contact information, please click here.
Click here to browse open positions.
Customer Service: Open 24 hours, 7 days a week Tel: 1.877.KNOW.INO (1.877.566.9466) Info@ikaria.com
Address: Perryville III Corporate Park 53 Frontage Road, Third Floor P.O. Box 9001 Hampton, NJ 08827-9001
Tel: 908.238.6600 Fax: 908.238.6633
INOMAX is a vasodilator, which, in conjunction with ventilatory support and other appropriate agents, is indicated for the treatment of term and near-term (>34 weeks) neonates with hypoxic respiratory failure associated with clinical or echocardiographic evidence of pulmonary hypertension, where it improves oxygenation and reduces the need for extracorporeal membrane oxygenation.
Utilize additional therapies to maximize oxygen delivery with validated ventilation systems.
Important Safety Information
Please see full Prescribing Information.
The INOMAX DSIR and INOMAX DSIR Plus Delivery Systems must only be used in accordance with the indications, usage, contraindications, warnings, and precautions described in the nitric oxide drug package inserts and labeling.